Dynamic MRI and CAD vs. choline MRS: Where is the detection level for a lesion characterisation in prostate cancer?

International Journal of Radiation Biology

Volumn 85, Issue 9, 2009, Pages 814-824

  Schmuecking, Michael ^a   Boltze, Carsten ^b   Geyer, Hagen ^a   Salz, Henning ^c   Schilling, Bert ^d   Wendt, Thomas G ^c   Kloetzer, Karl Heinz ^c   Marx, Christiane ^a  

^a Greiz County Hospital   (Germany)

^b University Teaching Hospital   (Germany)

^c FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^d Practice for Radiation Oncology   (Germany)

Author keywords

CAD; Choline MRS; Choline PET CT; Dynamic MRI; IMRT; Prostate cancer

Indexed keywords

CHOLINE; CYTOKERATIN; GADOLINIUM PENTETATE; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATITIS; PROTON NUCLEAR MAGNETIC RESONANCE; SENSITIVITY AND SPECIFICITY; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT PLANNING; TUMOR VOLUME;

AGED; BIOPSY; CHOLINE; DIAGNOSIS, COMPUTER-ASSISTED; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RADIOTHERAPY, INTENSITY-MODULATED; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 70249134009     PISSN: 09553002     EISSN: 13623095     Source Type: Journal    
DOI: 10.1080/09553000903090027     Document Type: Article

References (66)

1. Ataman F, Poortmans P, Davis JB, Bernier J, Giraud JY, Kouloulias VE, Pierart M, Bolla M. 2004. High conformality radiotherapy in Europe: Thirty-one centres participating in the quality assurance programme of the EORTC prostate trial 22991. European Journal of Cancer 40:2411-2416.
2. Baum C, Birkner M, Alber M, Paulsen F, Nüsslin F. 2005. Dosimetric consequences of the application of off-line setup error correction protocols and a hull-volume definition strategy for intensity modulated radiotherapy of prostate cancer. Radiotherapy and Oncology 76:35-42.
3. Baum C, Alber M, Birkner M, Nüsslin F. 2006. Robust treatment planning for intensity modulated radiotherapy of prostate cancer based on coverage probabilities. Radiotherapy and Oncology 78:27-35.
4. Beyersdorff D, Hamm B. 2005. MRI for troubleshooting detection of prostate cancer. Fortschritte auf dem Gebiet der Röntgen-strahlen und der bildgebenden Verfahren 177:788-795.
5. Beyersdorff D, Darsow U, Stephan C, Schnorr D, Loening S, Taupitz M. 2003. MRI of prostate cancer using three different coil systems: Image quality, tumor detection, and staging. Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren 175:799-805.
6. Boehmer D, Maingon P, Poortmans P, Baron MH, Miralbell R, Remouchamps V, Scrase C, Bossi A, Bolla M; EORTC radiation oncology group. 2006. Guidelines for primary radiotherapy of patients with prostate cancer. Radiotherapy and Oncology 79:259-269.
7. Bos LJ, van der Geer J, van Herk M, Mijnheer BJ, Lebesque JV, Damen EM. 2005. The sensitivity of dose distributions for organ motion and set-up uncertainties in prostate IMRT. Radiotherapy and Oncology 76:18-26.
8. Breeuwsma AJ, Pruim J, Jongen MM, Suurmeijer AJ, Vaalburg W, Nijman RJ, de Jong IJ. 2005. In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 32:668-673.
9. Claus FG, Hricak H, Hattery RR. 2004. Pretreatment evaluation of prostate cancer: Role of MR imaging and 1H MR spectroscopy. Radiographics 24:S167-180.
10. de Crevoisier R, Tucker SL, Dong L, Mohan R, Cheung R, Cox JD, Kuban DA. 2005. Increased risk of biochemical and local failure in patients with distended rectum on the planning CT for prostate cancer radiotherapy. International Journal of Radiation Oncology Biology Physics 62:965-973.
11. De Meerleer G, Villeirs G, Bral S, Paelinck L, De Gersem W, Dekuyper P, De Neve W. 2005. The magnetic resonance detected intraprostatic lesion in prostate cancer: Planning and delivery of intensity-modulated radiotherapy. Radiotherapy and Oncology 75:325-333.
12. De Meerleer G, Fonteyne V, Meersschout S, Van den Broecke C, Villeirs G, Lumen N, Ost P, Vandecasteele K, De Neve W. 2008. Salvage intensity-modulated radiotherapy for rising PSA after radical prostatectomy. Radiotherapy and Oncology 89: 205-213.
13. Dhingsa R, Qayyum A, Coakley FV, Lu Y, Jones KD, Swanson MG, Carroll PR, Hricak H, Kurhanewicz J. 2004. Prostate cancer localization with endorectal MR imaging and MR spectroscopic imaging: Effect of clinical data on reader accuracy. Radiology 230:215-220. (Pubitemid 37549804)
14. Engelbrecht MR, Jager GJ, Laheij RJ, Verbeek AL, van Lier HJ, Barentsz JO. 2002. Local staging of prostate cancer using magnetic resonance imaging: A meta-analysis. European Radiology 12:2294-2302.
15. Farsad M, Schiavina R, Castellucci P, Nanni C, Corti B, Martorana G, Canini R, Grigioni W, Boschi S, Marengo M, Pettinato C, Salizzoni E, Monetti N, Franchi R, Fanti S. 2005. Detection and localization of prostate cancer: Correlation of (11)C-choline PET/CT with histopathologic step-section analysis. Journal of Nuclear Medicine 46:1642-1649.
16. Fischer BM, Olsen MW, Ley CD, Klausen TL, Mortensen J, Højgaard L, Kristjansen PE. 2006. How few cancer cells can be detected by positron emission tomography? A frequent question addressed by an in vitro study. European Joural of Nuclear Medicine and Molecular Imaging 33:697-702.
17. Fuchsjäger M, Shukla-Dave A, Akin O, Barentsz J, Hricak H. 2008. Prostate cancer imaging. Acta Radiologica 49:107-120.
18. Fütterer JJ, Heijmink SW, Scheenen TW, Veltman J, Huisman HJ, Vos P, Hulsbergen-Van de Kaa CA, Witjes JA, Krabbe PF, Heerschap A, Barentsz JO. 2006. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 241:449-458.
19. Fütterer JJ, Engelbrecht MR, Huisman HJ, Jager GJ, Hulsbergen-van De Kaa CA, Witjes JA, Barentsz JO. 2005. Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: Experienced versus less experienced readers. Radiology 237:541-549.
20. Fütterer JJ, Scheenen TW, Huisman HJ, Klomp DW, van Dorsten FA, Hulsbergen-van de Kaa CA, Witjes JA, Heerschap A, Barentsz JO. 2004. Initial experience of 3 tesla endorectal coil magnetic resonance imaging and 1H-spectroscopic imaging of the prostate. Investigative Radiology 39:671-680.
21. Galalae RM, Martinez A, Mate T, Mitchell C, Edmundson G, Nuernberg N, Eulau S, Gustafson G, Gribble M, Kovács G. 2004. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. International Journal Radiation Oncology Biology Physics 58:1048-1055.
22. Glunde K, Ackerstaff E, Mori N, Jacobs MA, Bhujwalla ZM. 2006. Choline phospholipid metabolism in cancer: Consequences for molecular pharmaceutical interventions. Molecular Pharmaceutics 3:496-506. (Pubitemid 44639126)
23. Grosu AL, Piert M, Weber WA, Jeremic B, Picchio M, Schratzenstaller U, Zimmermann FB, Schwaiger M, Molls M. 2005. Positron emission tomography for radiation treatment planning. Strahlentherapie und Onkologie 181:483-499.
24. Hara N, Okuizumi M, Koike H, Kawaguchi M, Bilim V. 2005. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a useful modality for the precise detection and staging of early prostate cancer. Prostate 62:140-147.
25. Hanley JA, McNeil BJ. 1982. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143:29-36.
26. Hricak H. 2005. MR imaging and MR spectroscopic imaging in the pre-treatment evaluation of prostate cancer. British Journal of Radiology 78:S103-111. (Pubitemid 43019918)
27. Hricak H, Choyke PL, Eberhardt SC, Leibel SA, Scardino PT. 2007. Imaging prostate cancer: A multidisciplinary perspective. Radiology 243:28-53.
28. Huisman HJ, Fütterer JJ, van Lin EN, Welmers A, Scheenen TW, van Dalen JA, Visser AG, Witjes JA, Barentsz JO. 2005. Prostate cancer: Precision of integrating functional MR imaging with radiation therapy treatment by using fiducial gold markers. Radiology 236:311-317.
29. Jacob R, Hanlon AL, Horwitz EM, Movsas B, Uzzo RG, Pollack A. 2004. The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer. Cancer 100:538-543.
30. Jacob R, Hanlon AL, Horwitz EM, Movsas B, Uzzo RG, Pollack A. 2005. Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement. International Journal ofRadiation Oncology Biology Physics 61:695-701.
31. Kiessling F, Lichy M, Grobholz R, Heilmann M, Farhan N, Michel MS, Trojan L, Ederle J, Abel U, Kauczor HU, Semmler W, Delorme S. 2004. Simple models improve the discrimination of prostate cancers from the peripheral gland by T1-weighted dynamic MRI. European Radiology 14:1793-1801.
32. Kim JK, Hong SS, Choi YJ, Park SH, Ahn H, Kim CS, Cho KS. 2005. Wash-in rate on the basis of dynamic contrast-enhanced MRI: Usefulness for prostate cancer detection and localization. Journal of Magnetic Resonance Imaging 22:639-646.
33. Kotzerke J, Volkmer BG, Glatting G, van den Hoff J, Gschwend JE, Messer P, Reske SN, Neumaier B. 2003. Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer. Nuklearmedizin 42:25-30.
34. Kupelian PA, Potters L, Khuntia D, Ciezki JP, Reddy CA, Reuther AM, Carlson TP, Klein EA. 2004. Radical prosta-tectomy, external beam radiotherapy 572 Gy, external beam radiotherapy 4or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. International Journal of Radiation Oncology Biology Physics 58:25-33.
35. Kurhanewicz J, Vigneron DB, Hricak H, Narayan P, Carroll P, Nelson SJ. 1996. Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. Radiology 198:795-805.
36. Martin T, Baltas D, Kurek R, Röddiger S, Kontova M, Anagnostopoulos G, Dannenberg T, Buhleier T, Skazikis G, Tunn U, Zamboglou N. 2004. 3-D conformal HDR brachytherapy as monotherapy for localized prostate cancer. A pilot study. Strahlentherapie und Onkologie 180:225-232.
37. Mazaheri Y, Shukla-Dave A, Hricak H, Fine SW, Zhang J, Inurrigarro G, Moskowitz CS, Ishill NM, Reuter VE, Touijer K, Zakian KL, Koutcher JA. 2008. Prostate cancer: Identifica-tion with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging - correlation with pathologic findings. Radiology 246:480-488.
38. Mock U, Bogner J, Georg D, Auberger T, Pötter R. 2005. Comparative treatment planning on localized prostate carcinoma conformal photon- versus proton-based radiotherapy. Strahlentherapie und Onkologie 181:448-455.
39. Morgan PB, Hanlon AL, Horwitz EM, Buyyounouski MK, Uzzo RG, Pollack A. 2007. Radiation dose and late failures in prostate cancer. International Journal of Radiation Oncology Biology Physics 67:1074-1081.
40. Nestle U, Kremp S, Grosu AL. 2006. Practical integration of [18F]-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC): The technical basis, ICRU-target volumes, problems, perspectives. Radiotherapy and Oncology 81:209-225.
41. Northwood IC, Tong AH, Crawford B, Drobnies AE, Cornell RB. 1999. Shuttling of CTP:Phosphocholine cytidylyltransferase between the nucleus and endoplasmic reticulum accompanies the wave of phosphatidylcholine synthesis during the G(0)- 4G(1) transition. The Journal of Biological Chemistry 274:26240-26248.
42. Okamura T, Umemoto Y, Yamashita K, Suzuki S, Shirai T, Hashimoto Y, Kohri K. 2006. Pitfalls with MRI evaluation of prostate cancer detection: Comparison of findings with histopathological assessment of retropubic radical prostatect-omy specimens. Urologia Internationalis 77:301-306.
43. Pellizzon AC, Salvajoli J, Novaes P, Maia M, Fogaroli R, Gides D, Horriot R. 2008. The relationship between the biochemical control outcomes and the quality of planning of high-dose rate brachytherapy as a boost to external beam radiotherapy for locally and locally advanced prostate cancer using the RTOG-ASTRO Phoenix definition. International Journal of Medical Sciences 5:113-120.
44. Poortmans P, Bossi A, Vandeputte K, Bosset M, Miralbell R, Maingon P, Boehmer D, Budiharto T, Symon Z, van den Bergh AC, Scrase C, Van Poppel H, Bolla M; EORTC Radiation Oncology Group. 2007. Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group. Radiotherapy and Oncology 84:121-127.
45. Reske SN, Blumstein NM, Neumaier B, Gottfried HW, Fin-sterbusch F, Kocot D, Möller P, Glatting G, Perner S. 2006. Imaging prostate cancer with 11C-choline PET/CT. Journal of Nuclear Medicine 47:1249-1254.
46. Sala E, Eberhardt SC, Akin O, Moskowitz CS, Onyebuchi CN, Kuroiwa K, Ishill N, Zelefsky MJ, Eastham JA, Hricak H. 2006. Endorectal MR imaging before salvage prostatectomy: Tumor localization and staging. Radiology 238:176-183.
47. Schaefer A, Kremp S, Hellwig D, Rübe C, Kirsch CM, Nestle U. 2008. A contrast-oriented algorithm for FDG-PET-based delineation of tumour volumes for the radiotherapy of lung cancer: Derivation from phantom measurements and validation in patient data. European Journal of Nuclear Medicine and Molecular Imaging 35:1989-1999.
48. Schlemmer HP, Merkle J, Grobholz R, Jaeger T, Michel MS, Werner A, Rabe J, van Kaick G. 2004. Can pre-operative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens? European Radiology 14:309-317.
49. Schmuecking M, Mentzel HJ, Bloch BN, Scheithauer M, Schilling B, Salz H, Kaiser WA, Wendt TG. 2006. A novel approach of combined high resolution T2-w and parametrically analyzed dynamic contrast enhanced T1-w MR imaging for radiation treatment planning of the prostate. Strahlentherapie und Onkologie 182:78S.
50. Schmuecking M, Baum RP, Bonnet R, Junker K, Mueller KM. 2005. Correlation of histologic results with PET findings for tumor regression and survival in locally advanced non-small cell lung cancer after neoadjuvant treatment. Pathologe 26:178-189.
51. Shukla-Dave A, Hricak H, Eberhardt SC, Olgac S, Muruganand-ham M, Scardino PT, Reuter VE, Koutcher JA, Zakian KL. 2004. Chronic prostatitis: MR imaging and 1H MR spectroscopic imaging findings - initial observations. Radiology 231: 717-724.
52. Symon Z, Griffith KA, McLaughlin PW, Sullivan M, Sandler HM. 2003. Dose escalation for localized prostate cancer: Substantial benefit observed with 3D conformal therapy. International Journal of Radiation Oncology Biology Physics 57:384-390.
53. Tanderup K, Olsen DR, Grau C. 2006. Dose painting: Art or science? Radiotherapy and Oncology 79:245-248.
54. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HB, Lee TY, Mayr NA, Parker GJ, Port RE, Taylor J, Weisskoff RM. 1999. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: Standardized quantities and symbols. Journal of Magnetic Resonance Imaging 10:223-232.
55. Tofts PS. 1997. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. Journal of Magnetic Resonance Imaging 7:91-101.
56. Villeirs GM, Verstraete KL, De Neve WJ, De Meerleer GO. 2005a. Magnetic resonance imaging anatomy of the prostate and periprostatic area: A guide for radiotherapists. Radiotherapy and Oncology 76:99-106.
57. Villeirs GM, Van Vaerenbergh K, Vakaet L, Bral S, Claus F, De Neve WJ, Verstraete KL, De Meerleer GO. 2005b. Inter-observer delineation variation using CT versus combined CT +MRI in intensity-modulated radiotherapy for prostate cancer. Strahlentherapie und Onkologie 181:424-430.
58. Wang L, Hricak H, Kattan MW, Chen HN, Scardino PT, Kuroiwa K. 2006. Prediction of organ-confined prostate cancer: Incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. Radiology 238:597-603.
59. Wefer AE, Hricak H, Vigneron DB, Coakley FV, Lu Y, Wefer J, Mueller-Lisse U, Carroll PR, Kurhanewicz J. 2000. Sextant localization of prostate cancer: Comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. Journal of Urology 164:400-404. (Pubitemid 30481935)
60. Wu X, Dibiase SJ, Gullapalli R, Yu XC. 2004. Deformable image registration for the use of magnetic resonance spectroscopy in prostate treatment planning. International Journal of Radiation Oncology Biology Physics 58:1577-1583.
61. Yamaguchi T, Lee J, Uemura H, Sasaki T, Takahashi N, Oka T, Shizukuishi K, Endou H, Kubota Y, Inoue T. 2005. Prostate cancer: A comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy. European Journal of Nuclear Medicine and Molecular Imaging 32:742-748.
62. Yu KK, Scheidler J, Hricak H, Vigneron DB, Zaloudek CJ, Males RG, Nelson SJ, Carroll PR, Kurhanewicz J. 1999. Prostate cancer: Prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology 213:481-488. (Pubitemid 29510596)
63. Zelefsky MJ, Fuks Z, Hunt M, Yamada Y, Marion C, Ling CC, Amols H, Venkatraman ES, Leibel SA. 2002. High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients. International Journal of Radiation Oncology Biology Physics 53:1111-1116.
64. Zelefsky MJ, Fuks Z, Hunt M, Lee HJ, Lombardi D, Ling CC, Reuter VE, Venkatraman ES, Leibel SA. 2001. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. Journal of Urology 166:876-881. (Pubitemid 32750970)
65. Zhao D, Jiang L, Hahn EW, Mason RP. 2005. Tumor physiologic response to combretastatin A4 phosphate assessed by MRI. International Journal of Radiation Oncology Biology Physics 62:872-880.
66. Zaider M, Zelefsky MJ, Lee EK, Zakian KL, Amols HI, Dyke J, Cohen G, Hu Y, Endi AK, Chui C, Koutcher JA. 2000. Treatment planning for prostate implants using magnetic-resonance spectroscopy imaging. International Journal of Radiation Oncology Biology Physics 47:1085-1096.